Company Overview of Intercell Ag
As of May 28, 2013, Intercell Ag was acquired by Vivalis. Intercell AG, a biotechnology company, develops and commercializes novel immunomodulatory biologicals to prevent disease and reduce suffering worldwide. Its technology platforms include the patch-based vaccine delivery system and the proprietary human monoclonal antibody discovery system, eMAB. It offers Japanese Encephalitis, an inactivated vaccine indicated for active immunization for the prevention of disease caused by the Japanese Encephalitis virus in adults under the IXIARO and JESPECT brand names. Intercell AG’s Japanese Encephalitis vaccine is also completed Phase III clinical trial for pediatric use in non-endemic markets. Th...
Campus Vienna Biocenter 3
Key Executives for Intercell Ag
Intercell Ag does not have any Key Executives recorded.
Intercell Ag Key Developments
Intercell Ag(WBAG:ICLL) dropped from ATX Prime Index
May 28 13
Intercell Ag will be removed from ATX Prime Index
Intercell Ag to Report Q1, 2013 Results on May 31, 2013
May 6 13
Intercell Ag announced that they will report Q1, 2013 results on May 31, 2013
Intercell Ag Reports Preliminary Earnings Results for the Full Year 2012
Mar 5 13
Intercell Ag reported preliminary earnings results for the full year 2012. For the year, the company’s total revenue increased by 8.5% to EUR 35.7 million. Revenue growth and further cost savings led to reduction of full year 2012 net loss to EUR 25.3 million compared to EUR 29.3 million in 2011.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries